Welcome : Guest

GlobeImmune, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about GlobeImmune, Inc., which is principally involved in Biopharmaceuticals Business. Illustrated with 72 tables, the report showcases the company's key markets and market position as against its competitors operating in the industry.

Code: PCP-64469
Price: $3500
Company Type: Public
Pages: 77
Date: November 2016
Market Data Tables: 72

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Hepatitis B......6
Table 1: No. of Hepatitis B Patients by Region in Europe (2015) - Percentage Market Share Breakdown by Volume for Eastern Europe, and Western Europe......6
Table 2: No. of Hepatitis B Patients by Country in Eastern Europe (2015) - Percentage Market Share Breakdown by Volume for Hungary, Poland, and Romania......7
Table 3: No. of Hepatitis B Patients by Country in West Europe (2015) - Percentage Market Share Breakdown by Volume for France, Germany, Italy, Netherlands, Spain, United Kingdom, and Others......8
Hepatitis C......9
Table 4: Hepatitis C Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Immuno Modulator, Polymerase Inhibitor, Protease Inhibitors, and Others (Includes Ribavirin)......9
Table 5: Hepatitis C Market by Genotype Worldwide (2015) - Percentage Share Breakdown by Value for Genotype 1, Genotype 2 and Others......10
Table 6: Hepatitis C Virus Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Immuno-Modulator, Polymerase Inhibitor, Protease Inhibitors, Ribavirin, and Others......11
Table 7: Hepatitis C Virus Market by Patient Conditions in Europe (2015) - Percentage Share Breakdown by Value for Diagnosed, Prevalence, Under Care and Others......12
Table 8: No. of Hepatitis C Virus (HCV) Patients by Category in European Union (EU) (2015) - Percentage Market Share Breakdown for GT1, and Non-GT1......13
Table 9: Hepatitis C Virus Market by Patient Conditions in the US (2015) - Percentage Share Breakdown by Value for Diagnosed, Prevalence, Under Care and Others......14
Table 10: Health Insurance for Hepatitis C Virus (HCV) by Type in the US (2015) - Percentage Market Share Breakdown by Value for Commercial, Dual (Medicare and Medicaid), Medicaid, Medicare (Non- Dual), Prison, Uninsured, and Veteran Affairs......15
Table 11: No. of Hepatitis C Virus (HCV) Patients by Category in the US (2015) - Percentage Market Share Breakdown for GT1 HCV, GT2/3 HCV, and Others......16
Infectious Disease Drugs......17
Table 12: nfectious Disease Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value Sales for Molecular Diagnostics Infectious Diseases, and Others......17
Table 13: Infectious Disease Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Antifungals, Antivirals, Cephalosporins, Macrolides, Penicillins, Quinolones, and Others......18
HIV Drugs......19
Table 14: HIV Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)/ Nucleoside Reverse Transcriptase Inhibitor (NRTI) Fixed Dose Combination (FDC), Nucleoside Reverse Transcriptase Inhibitor (NRTI)/Retroviral Integrase/CYP3A, Nucleoside Reverse Transcriptase Inhibitor (NRTIs), Protease Inhibitors, Retroviral Integrase (IN), and Others (Includes NNRTIs)......19
Table 15: HIV Regimens for New Start Patients by Segment in European Union (2015) - Percentage Market Share Breakdown by Value Sales for Atripla, Compler, Stribild, Truvada and Others......20
Table 16: HIV Regimens for Experienced Patients by Segment in the US (2015) - Percentage Market Share Breakdown by Value Sales for Atripla, Stribild, Truvada and Others......21
Table 17: HIV Regimens for New Start Patients by Segment in the US (2015) - Percentage Market Share Breakdown by Value Sales for Atripla, Compler, Stribild, Truvada and Others......22
Immunotherapy......23
Table 18: No. of Patients for Immunotherapy by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Europe, North America, and Others......23
Table 19: No. of Patients for Immunotherapy by Age Group in the US (2015) - Percentage Market Share Breakdown by Value for 0-4 Patient Pool, 10 - 14 Patient Pool, 15 - 19 Patient Pool, 5-9 Patient Pool, Adult Patient Pool (over 65), and Adult Patient Pool (under 65)......24
Table 20: Immunotherapy Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for Subcutaneous, and Sublingual......25
Table 21: Immunotherapy Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union, United States and Rest of the World......26
Cancer Drugs......27
Table 22: Oncology/Hematology Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Cell Factors, Chemopreventatives, Chemotherapeutics, Mabs, Targeted Therapies, and Others......27
Table 23: Oncology Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union Five, Japan, US and Others......28
Cancer Market......29
Table 24: Cancer Care Expenditure by Site Worldwide (2015) - Percentage Share Breakdown for Breast, Colorectal, Lymphoma, Lung, Prostate and Others......29
Table 25: Cancer Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Heme, Lung, Prostate, and Others......30
Table 26: Oncology Market by Cancer Type Worldwide (2015) - Percentage Share Breakdown by Value for Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, and Others......31
Table 27: Clinical Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......32
Table 28: Hereditary Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......33
Table 29: Cancer Market by Type in China (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Esophagus, Liver, Lung, Stomach and Others......34
Table 30: Oncology Market by Category in China (2015) - Percentage Share Breakdown by Value for Anti- Tumor Agents, Hormone Therapy, Immuno Suppresants and Immunostimulants......35
Table 31: Oncology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Solid Tumor and Others......36
Cancer Patients......37
Table 32: Breast Cancer Diagnoses by Hospital Type in the US (2015) - Percentage Share Breakdown by Volume for Community, Comprehensive, Teaching and Research, and Others......37
Table 33: No. of Colorectal Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......38
Table 34: No. of Invasive Breast Cancer Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......39
Table 35: No. of Primary Liver Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......40
Table 36: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Imbruvica PCYC, Rituxan, Gazyva ROG, and Others......41
Table 37: No. of Cutaneous Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......42
Table 38: No. of Ocular Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......43
Table 39: Female Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Lung, Breast, Colon, Rectum and Anus, Intestine, Liver, and Others......44
Table 40: Male Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Colon, Colon, Rectum and Anus, Intestine, Liver, Lung, and Others......45
Table 41: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......46
Table 42: No. of Chronic Lymphocytic Leukemia (CLL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......47
Table 43: No. of Cancer Patients by Type in the US (2015) - Percentage Market Share Breakdown for Colorectal Cancer (CRC), Melanoma, Non-Squamous Non-Small-Cell Lung Cancer (NSCLC), Ovarian, Prostate, Renal Cell Carcinoma (RCC), and Squamous Non-Small-Cell Lung Cancer (NSCLC)......48
Table 44: Number of Cancer Patients by Type in the US (2015) - Percentage Share Breakdown by Volume for Bladder Cancer, Breast Cancer (Female), Colon and Rectum Cancer, Endometrial Cancer, Kidney and Renal Pelvis Cancer, Lung and Bronchus Cancer, Melanoma of the Skin, Non-Hodgkin Lymphoma, Prostate Cancer, and Thyroid Cancer......49
Table 45: No. of Cancer Patients Death by Type in the US (2015) - Percentage Share Breakdown for Breast, Colorectal, Lung, Melanoma, and Prostate......50
Table 46: New Patients with Cancer by Site in the US (2015) - Percentage Market Share Breakdown by volume for Colorectal, Lung and Bronchus, Melanoma, Pancreas, and Others......51
Table 47: Number of Cancer Patients by Type Worldwide (2015) - Percentage Share Breakdown by Volume for Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Non-Hodgkin lymphoma, Oesophagus, Prostate, and Stomach......52
Table 48: No. of Bladder Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Invasive Patients, and Non-Invasive Patients......53
Table 49: No. of Invasive Breast Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......54
Table 50: New Patients with Cancer in Stage 3/4 by Site in the US (2015) - Percentage Market Share Breakdown by Volume for Colorectal, Lung and Bronchus, Pancreas and Others......55
Table 51: No. of Solid Cancer Tumor Patients by Type Worldwide (2015) - Percentage Share Breakdown for Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer......56
Table 52: No. of Non Small Cell Lung Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I, Stage II-III, Stage III-IV, and Undiagnozed......57
Cervical Cancer......58
Table 53: Cervical Cancer Market by HPV Type in England (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 33, HPV 45, and Others......58
Table 54: Cervical Cancer Market by HPV Type in Europe (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 31, HPV 33, and Others......59
Hematological Cancer......60
Table 55: Hematological Cancer by Category Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), and Non-Hodgkin’s Lymphoma (NHL)......60
Skin Cancer......61
Table 56: Skin Cancer by Type Worldwide (2015) - Percentage Market Share Breakdown by Volume for Basal Cell Carcinomas, Melanoma, and Squamous Cell Carcinomas......61
Cancer-Associated Mucositis......62
Table 57: Cancer-Associated Mucositis Market by Activity Worldwide (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Head and Neck, Non-Small Cell Lung cancer and Others......62
Chronic Myelogenous Leukemia (CML)......63
Table 58: Chronic Myelogenous Leukemia (CML) Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for Asia-Pacific, Canada, European Union, Japan, USA, and Others......63
Multiple Myeloma......64
Table 59: Multiple Myeloma by Age Group Worldwide (2015) - Percentage Share Breakdown by No. of New Cases for 45-54, 55-64, 65-74, 75-84, >84, and Others......64
Table 60: Multiple Myeloma Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Kyprolis AMGN, Pomalyst CELG, Revlimid CELG, Thalomid CELG, and Velcade TKD/JNJ......65
Cancer Drugs......66
Table 61: Market Shares of Leading Oncology Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co., and Others......66
Table 62: Market Shares of Leading Oncology/Hematology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......67
Table 63: Market Shares of Leading Oncology Drug Manufacturers in China (2015) - Percentage Share Breakdown by Value for Astrazeneca, Jiangsu Hengrui Medicine Co., Ltd., Roche Group and Others......68
Table 64: Anti-Cancer Drugs Market by Product Type in China (2015) - Percentage Share Breakdown by Value for Anastrozole, Capecitabine, Cetuximab, Compound kushen, Docetaxel, Epirubicin, Erlotinib, Gefitinib, Gemcitabine, Goserelin, Interferon α-2a, Interferon α-2b, Irinotecan, Kangai, Lentinan, Letrozole, Oxaliplatin, Paclitaxel, Pemetrexed, Pidotimod, RhG-CSF, RhIL-2, Rituximab, Sorafenib, Sshenqi Fuzheng, Thymopentin, Thymosin a1, Trastuzmmab, Triptorelin, TS-1, and Others......69
Table 65: Anti-Cancer Drugs Market by Type in China (2015) - Percentage Share Breakdown by Value for Alkylating Agents, Antibiotics, Antimetabolites, Hormonal Agents, Immunostimulant, Plant Alkaloids, and Others......70
Breast Cancer Drugs......71
Table 66: Market Shares of Leading Breast Cancer Drugs by Value Sales in China (2014) - Percentage Breakdown for Alkylating Agents, Antimetabolite, Antitumor Antibiotics, Antitumor Antihormone, Antitumor Botanicals, Monoclonal Antibodies, Targeted Small Molecule Agents, and Others......71
Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL)......72
Table 67: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......72
Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL)......73
Table 68: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Other......73
Table 69: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib and Other......74
Hepatitis B Drugs......75
Table 70: Market Shares of Leading Hepatitis B Drug Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for Bemis Company, Inc.(Baraclude), F. Hoffmann-La Roche AG (Pegasys), GlaxoSmithKline Plc (Hepsera, Zeffix), and Novartis International AG (Sebivo)......75
Table 71: Market Shares of Leading Hepatitis B Drug Manufacturers by Value Sales in Korea (2014) - Percentage Breakdown for Bemis Company, Inc. (BMS), Bukwang Pharmaceutical Co., Ltd (Levovir), GlaxoSmithKline Plc (Hopsera, Zeffix), Novartis International AG (Sebivo), and Others......76
Infectious Disease Drugs......77
Table 72: Market Shares of Leading Infectious Disease Drugs Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, AstraZeneca Plc, Bristol- Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Forest Laboratories, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......77